StockNews.AISignal intelligence
Neogen Corporation · NASDAQ · Healthcare
Browse public NEOG signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Neogen Corporation is set to release its Q3 earnings on April 9, with analysts expecting a drop in earnings per share to 5 cents, down from 10 cents last year. The anticipated revenue of $204.62 million also signifies a decline. The company's recent sale of its Genomics business to Zoetis adds another layer to its financial outlook.
View signal analysisNeogen Corporation has initiated a nationwide recall of all unexpired lots of its Neogen Vet HYCOAT product due to identified microbial contamination. This significant move could negatively affect the company’s sales and reputation in the veterinary market, posing a near-term risk to its stock performance.
View signal analysisNEOG beat Q2 earnings estimates at 10 cents per share, consensus was 6 cents. Sales decreased by 2.8% YoY but outperformed expectations at $224.69 million. Food Safety segment revenue increased 0.8%, driven by strong Petrifilm sales. Animal Safety segment fell 11.8% due to lower needle and syringe sales. Fiscal 2026 sales guidance raised to $845-$855 million, above consensus $823.30 million.
View signal analysisNEOG reported Q1 2026 sales of $209.19 million, slightly above expectations. Gross margin fell to 45.4% due to production relocations and tariffs. First-quarter adjusted EBITDA was $35.5 million, lower than last year's $43.7 million. Food Safety sales declined 4.6%, while Genomics showed mid-single-digit growth. NEOG affirmed 2026 sales guidance of $820-$840 million, slightly above consensus.
View signal analysisNEOG earnings expected at 4 cents, down from 7 cents last year. Projected quarterly revenue is $204.15 million, down from $216.96 million. Shares fell 7.1%, closing at $5.63 following CFO Naemura's departure announcement. Analysts have mixed ratings; some downgraded while others maintain 'Buy' outlook.
View signal analysis